The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the second thing is the specificity particularly when you compare it to the proteins where as we mentioned like psa can be made by normal prostate cells and by prostate cancer cells but the mutations in a prostate cancer would not be present in the normal prostate cells they would be present in the cancer cells so how do we tell then if there's circulating intermediate present is that we look for mutations in these short dna molecules
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and the second thing is the specificity particularly when you compare it to the proteins where as we mentioned like psa can be made by normal prostate cells and by prostate cancer cells but the mutations in a prostate cancer would not be present in the normal prostate cells they would be present in the cancer cells